Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss
02:49pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Axsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval for its lead candidate AXS-05 by second-quarter 2022 to treat major depressive disorder.
Can Deciphera Pharmaceuticals, Inc. (DCPH) Climb 79% to Reach the Level Wall Street Analysts Expect?
01:55pm, Monday, 02'nd May 2022 Zacks Investment Research
The consensus price target hints at a 78.9% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward tre
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
07:12pm, Friday, 29'th Apr 2022 Zacks Investment Research
AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
06:25pm, Friday, 29'th Apr 2022 Zacks Investment Research
Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up
06:53pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
06:35pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
12:45pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Raises $150M Via Equity Offering
07:55am, Wednesday, 27'th Apr 2022
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) has priced an underwritten public offering of 5.25 million shares at $10.00 per share, for gross proceeds of $150 million. The offer price represents a d
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
07:01pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio
04:08pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.
4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio
01:32pm, Friday, 22'nd Apr 2022
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.
The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals
11:39am, Friday, 22'nd Apr 2022 Zacks Investment Research
Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
11:19am, Thursday, 21'st Apr 2022
Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 73%: Read This Before Placing a Bet
01:55pm, Friday, 15'th Apr 2022 Zacks Investment Research
The mean of analysts' price targets for Deciphera Pharmaceuticals, Inc. (DCPH) points to a 73.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 73%: Read This Before Placing a Bet
11:17am, Friday, 15'th Apr 2022
The mean of analysts' price targets for Deciphera Pharmaceuticals, Inc. (DCPH) points to a 73.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong
